rebioin journal
OF BIOSCIENCES

ADVANCES AND FUTURE PROSPECTS IN BIOTECHNOLOGY AND BIOPHARMACEUTICALS: FROM BENCH TO BEDSIDE

admin@reboin.com

www.rebioin.com

Advances and Future Prospects in Biotechnology and Biopharmaceuticals: From Bench to Bedside

Chandan Kumar M N[1], Gargi V J[1], Kushi N[1], Nisarga R[1], Sharanu Gouda[1], Annie Jessica Toppo[2]
JSS College of Arts, Commerce and Science, Mysore[1], Rapture Biotech Bengaluru[2]
Corresponding Author: rapturetrainer.bengaluru@gmail.com

Abstract

Biopharmaceuticals, encompassing biologics and biosimilars, are revolutionizing the management of chronic and complex diseases. Produced through recombinant DNA, mammalian and yeast systems, plant platforms, and emerging cell-free synthesis, they require stringent analytical and quality control measures to ensure safety and efficacy. Innovations such as monoclonal antibodies, mRNA therapeutics, and CAR-T cell therapy are driving rapid clinical and market growth, though challenges remain in cost, manufacturing, and access. Future progress in precision medicine, gene and cell therapies, artificial intelligence, and human genetics research promises to further advance patient care and global healthcare outcomes.

Keywords: Biopharmaceuticals, biotechnology, Biologics, Biosimilars, Recombinant DNA technology, Monoclonal antibodies, mRNA therapeutics

1. Introduction :

Biotechnology, an interdisciplinary field involves technical application of living organisms in various sectors one of which is pharmaceuticals [1]. Throughout the years Pharmaceuticals have emerged from empiricism and have progressed rapidly becoming one of the most promising fields [2]. Biopharmaceuticals involve the use of living organisms, biomolecules as therapeutic agents. They were introduced in 1982 and since then they have been used in the treatment of a broad spectrum of diseases [3].

These fields have been evolving which such advancement, it has made diagnosis, treatment or curing diseases safer, better and easier over the years. The development of new techniques and discovery of new methods have contributed for a much better lifestyle of human health [4].

From lab discoveries to life-saving therapies a limitless journey of ground breaking future lies ahead of the biotechnology and biopharmaceutical industry.

1.1 Types of biopharmaceuticals

Biopharmaceuticals are large, complex molecule drugs that are hundreds of times the size of conventional small-molecule pharmaceuticals. These drugs are administered through injection or infusion and are used to treat chronic or debilitating conditions where traditional therapies often have limited effectiveness [5].

There are two main types of biopharmaceuticals: biologics and biosimilars. Biologics are produced from living organisms and may be composed of proteins, sugars, nucleic acids, or combinations of these substances. They can also include living cells or tissues used in cell or tissue therapy. These products are derived from various natural sources such as humans, animals, or microorganisms and are manufactured using advanced biotechnology processes [6].

Due to their complexity and therapeutic value, many biologics are protected by patents. Once these patents expire, they open the door for the development of biosimilars, which are cost-effective alternatives designed to closely mimic the original biologic. Although biosimilars may differ slightly in structure, they contain the same active substances and show no significant difference in terms of safety, efficacy, dosage, or administration route. Typically, biosimilars are 20 to 30 percent less expensive than their reference products. A notable example is Zarxio [filgrastism], the first biosimilar approved by the USFDA in 2015 as an alternative to Neupogen. Currently, more than 50 biosimilar products are under development, highlighting their growing importance in modern therapeutics [7].

1.2 Production technologies of Biopharmaceuticals:

In the field of biotechnology, the emergence of rDNA technology is an established technique of producing biopharmaceuticals. Genentech's successful production of human insulin in *Escherichia coli* using rDNA technology in 1979 marked the first major application of rDNA by demonstrating that human proteins with therapeutic potential, even complex proteins such as heterodimeric insulin, could be produced in non-native hosts and successfully purified to generate a functional medicinal product with a favorable efficacy and safety profile [8].

Over the past decades, therapeutic monoclonal antibodies, recombinant enzymes, cytokines and blood-related proteins, most of which are produced in mammalian cells (Chinese hamster ovary cells, CHO). CHO cells are the predominant hosts for stable transfection and high efficiency production on a large scale [9]. CHO is a time-consuming, laborious and expensive process. Microbe expression system-derived recombinant proteins, on the other hand, face several limitations, such as post-translational modifications (PTMs), potential immunogenicity, poor stability and short serum half-life. One of the preferred heterologous expression systems are generally recognized as safe (GRAS) yeasts (e.g., *S. cerevisiae, Pichia pastoris, Yarrowia lipolytica, Hansenula polymorpha*), which are robust, easy to genetically manipulate, cost-effective, and unlike E. coli possess native PTM machinery and lack endotoxins [10].

Bacterial expression systems, yeast expression system and mammalian cell lines have their own merits and setbacks. Plants offer several potential benefits and prove the reliability of the system for the production of highly valuable biopharmaceuticals. Plants were utilized for the expression of recombinant proteins from the late 1980s. All plant-based systems are easy cultivation, low expenses, low or no pathogen load, rapid mass production of recombinant proteins, and the ability of the plants to assemble complex proteins with eukaryotic-like post-translational modifications. *Nicotiana benthamiana* and *N. tabacum* are two common species used for the stable and transient expression of recombinant proteins [11].

Cell-free protein synthesis (CFPS) technologies have grown from lab-scale research tools to biopharmaceutical production. Most modern-day biopharmaceuticals are produced using cell-based systems, typically either Chinese hamster ovary (CHO) mammalian cell cultures or *E. coli* microbial fermentations. In contrast, cell-free protein synthesis (CFPS) technologies activate the same fundamental biological processes without the constraints of a living cell. Removing the cell-wall barrier allows.

(1) direct monitoring and control of the complex reactions required for polypeptide synthesis.

(2) efficient protein folding, and, when required.

(3) post-translational modifications.

The conditions can be precisely optimized for each product, and energetic and molecular resources are not wasted on maintaining cell viability or making new cells. The unique, open nature of CFPS has enabled efficient non-natural amino acid (nnAA) incorporation into protein products, which expands the range of biotherapeutics that can be considered for novel treatments. The flexibility and speed of CFPS combined with novel nnAA capabilities are poised to open a new chapter in the continuing evolution of biotherapies [12].

2. Analytical Approaches

Analytical techniques are important in biotechnology and biopharmaceutical research to characterize drug properties such as solubility, purity, stability, and structural integrity. The following methods have been widely applied.

2.1 Solubility Characterization:

2.1.1 Shake flask: The shake flask (Fig 1) method is widely used to determine equilibrium solubility, providing reliable results, but it has drawbacks such as high sample requirements and being time-consuming [13].

Fig 1: Shake Flask

2.1.2 Miniaturised/ modified shake flask: The miniaturized shake-flask method was designed to determine solubility using only a small amount of sample, making it suitable when drug material is limited. Its simplicity and low cost are considered clear advantages, and it has shown to be both precise and reliable. This method is particularly useful in the early stages of drug discovery; however, it is less suitable for high-throughput screening since it can only process a limited number of compounds per week. Compared with the classical shake-flask method, it may provide slightly lower accuracy in determining thermodynamic solubility, but it remains a practical tool for preliminary biopharmaceutical characterization [13].

2.1.3 Miniaturised devices: A miniaturized device was developed to measure the solubility of six compounds with diverse chemical structures. Unlike the traditional shake-flask method, where drug adsorption to the filter membrane can be a significant limitation, this device minimizes adsorption because the drug slurry is continuously filtered through the membrane. This improvement enhances the reliability of solubility measurements and reduces the risk of underestimating the true solubility of the compounds [13].

2.1.4 Equilibrium solubility in 96-well plate: The equilibrium 96-well plate (Fig 2) method is a miniaturized, high-throughput approach that enables solubility testing of many compounds in parallel using very small sample volumes, though evaporation can affect accuracy [13].

Fig 2: 96-well plate

2.1.5 Column elution method: The column elution (Fig 3) method allows faster determination of solubility compared to traditional techniques, but it requires specialized equipment and may overestimate solubility if equilibrium is not fully achieved [13].



Fig 3: Column Elution

2.2 Monoclonal antibody characterization:

2.2.1. Chromatographic methods: Chromatographic techniques are widely applied for analyzing monoclonal antibodies. Size-exclusion chromatography (SEC) (Fig 4) is useful to detect aggregates, ensuring patient safety. Ion-exchange chromatography (IEX) separates charge variants and monitors product consistency. Affinity chromatography, such as Protein A-based methods, helps in purification and quantification. Reverse-phase HPLC and hydrophobic interaction chromatography provide information about purity, stability, and protein folding [14].



Fig 4: Size-exclusion chromatography

2.2.2 Electrophoretic methods: Electrophoretic techniques such as capillary electrophoresis, SDS-PAGE (Fig 5), and isoelectric focusing are widely used to study purity, molecular weight, and charge heterogeneity of monoclonal antibodies [14].



Fig 5: SDS-PAGE

2.2.3 Spectroscopic techniques: Spectroscopic methods like UV, fluorescence, circular dichroism, and FTIR provide information on concentration, stability, and structural integrity, ensuring correct folding and activity [14].

2.2.4 Electrochemical techniques: Electrochemical approaches, including immunosensors and voltammetry, offer sensitive and rapid detection of antibody interactions and concentrations (Fig 6) [14].



Fig 6: Biosensor Electrode

3. Quality control approaches

In addition to research applications, these analytical tools form the foundation of quality control (QC) in drug development. QC ensures that products remain safe, effective, and consistent for patient use.

3.1 Solubility testing

In biopharmaceuticals, solubility is an important quality factor because it affects how stable a drug is, how well it dissolves in the body, and how accurate the dose will be. For quality control, measuring *thermodynamic solubility* is most important since it shows the true solubility at equilibrium. The shake-flask method is still the most trusted for QC because it gives reliable and repeatable results, but sometimes errors can happen if the drug sticks to the filter. Newer miniaturised and high-throughput methods, like the 96-well plate or column elution, are faster and useful for early drug discovery, but they are not as good for QC because they may give less precise results or even higher solubility values than the real ones. Overall, QC needs methods that are tested and reliable so that the drug quality remains safe and consistent [13].

3.2 Monoclonal antibody quality control

In quality control, analytical techniques are applied to ensure monoclonal antibodies are safe, pure, and effective. Chromatography is mainly used to test purity, aggregation, and impurities. Electrophoretic methods check charge variants and molecular weight consistency. Spectroscopic techniques verify correct folding, structure, and stability of the antibody. Electrochemical methods, such as biosensors, are emerging tools for rapid detection and quantification. Together, these QC approaches guarantee batch-to-batch consistency and maintain therapeutic effectiveness [14].

4. Recent advancements in biopharmaceuticals.

The biopharmaceutical industry is undergoing rapid transformation driven by AI integration, mRNA platforms, gene and cell therapies, and personalised medicine. This explores ground-breaking innovations, regulatory shifts, and digital technologies shaping drug development, manufacturing, and patient-centric care, positioning biopharma at the forefront of next-generation healthcare evolution.

The biopharmaceutical industry is undergoing a profound transformation, marked by the convergence of biotechnology, computational sciences, and engineering. This dynamic evolution is being accelerated by innovations across multiple scientific disciplines, including genomics, artificial intelligence (AI), systems biology, precision engineering, and synthetic biology. Together, they are redefining how drugs are discovered, developed, manufactured, and delivered. One of the most significant shifts in this landscape is the diversification of the therapeutic pipeline. Traditional small molecules and monoclonal antibodies are now being augmented—and in some cases, replaced—by next-generation biologics such as bispecific antibodies, antibody-drug conjugates (ADCs), fusion proteins, and nucleic acid-based therapeutics. This paradigm shift allows for therapies that are not only more potent but also highly targeted, minimising off-target toxicity and improving patient outcomes, especially in complex disease states such as oncology, autoimmunity, and rare genetic disorders.

4.1 mRNA Therapeutics and Programmable Gene Modulation

The COVID-19 pandemic served as a catalyst for mRNA vaccine technology, but its potential extends far beyond infectious diseases. Current research is optimizing mRNA platforms for a wide array of applications including protein replacement therapies for genetic deficiencies, immuno-oncology, and in vivo gene editing. Self-amplifying mRNA (saRNA) and circular RNA (circRNA) technologies are emerging as next-generation platforms, offering prolonged expression and lower dosing requirements. Particularly exciting is the integration of programmable RNA-guided systems like CRISPR-Cas13, which target and edit RNA rather than DNA. This enables transient, reversible gene modulation with fewer off-target effects compared to DNA editing systems. Such tools are under preclinical evaluation for conditions ranging from spinal muscular atrophy to chronic viral infections [15].

5. Monoclonal Antibodies

Monoclonal antibodies (mAbs) have emerged as transformative agents in disease treatment, representing laboratory-produced proteins designed to mimic the immune system's natural antibodies that combat infections. Through precise targeting of specific molecules involved in disease processes, mAbs can impede their activity, modulate immune responses, or deliver therapeutic payloads to affected cells. Their notable success in treating conditions such as cancer, autoimmune diseases, and infectious diseases underscores their high specificity, reduced side effects, and potential for personalized medicine. Monoclonal antibodies have indeed revolutionized the treatment landscape, opening new avenues to enhance patient outcomes [16].

6. CAR-T Cell Therapy

AR-T cell therapy stands as a revolutionary paradigm in cancer treatment, leveraging the potency of the immune system. This ground-breaking therapy involves the modification of a patient's T cells, a type of immune cell, to express chimeric antigen receptors (CARs). These receptors empower T cells to recognize and precisely target cancer cells. Upon reintroduction into the patient, CAR-T cells undergo [16].

7. The Growth of Biopharmaceuticals Market

The global vaccines market is segmented based on technology, type, disease indication, end-users, and regions. Based on increasing company investments, the highest growth rate in the vaccines market is expected to be registered in the conjugate vaccines segment. Two conjugate vaccines against Streptococcus pneumoniae, Penavnar and Prevnar 13, already succeeded in the marked. The combined sales of these vaccines accounted for approximately $6,3 billion in 2015 which places them on the top of best-selling vaccines list (FIG-7) [17].

The top 10 best-selling biopharmaceuticals in 2016 included eight Abs (six mAbs and two Fc-based fusion proteins). The monoclonal antibody adalimumab (brand name Humira), a TNF-α inhibitor used to treat rheumatoid arthritis and related disorders, ranked first on this list, generating revenue of $16.486 billion. (FIG-7) [17].



Fig 7:Sales (US$ billion) of the five best-selling vaccines in 2015 and Sales (US$ billion) of the 10 best-selling biopharmaceuticals in 2016.(Kesik- brodacka 2017)

8. Regulatory Considerations

8.1 Preclinical and Clinical Trials

Biopharmaceuticals undergo extensive preclinical and clinical testing before market approval. **Good Laboratory Practice (GLP)** ensures the reliability of preclinical studies, while **Good Clinical Practice (GCP)** governs clinical trials to protect human subjects [18]. Clinical development typically progresses through Phases I–IV, ranging from safety testing in small groups to post-marketing surveillance [19].

8.2 Regulatory Agencies and Guidelines

- **United States:** The Food and Drug Administration (FDA), particularly the Center for Biologics Evaluation and Research (CBER), regulates biologics under the Public Health Service Act [19].
- **European Union:** The European Medicines Agency (EMA) provides centralized marketing authorization for biopharmaceuticals across member states [20].
- **India:** The Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) issue guidelines for biosimilars and biologics [21].
- **International Harmonization:** The International Council for Harmonisation (ICH) develops common technical standards to streamline approvals globally [18].

8.3 Quality and Safety Standards

- **Good Manufacturing Practices (GMP):** Ensure product purity, consistency, and absence of contamination [22].
- **Pharmacovigilance:** Post-marketing safety monitoring to detect adverse events [20].
- **Biosimilars:** Approval requires demonstrating similarity in structure, efficacy, and safety, not identical replication [23].

9. Ethical Considerations

9.1 Patient Rights and Informed Consent

Ethical conduct in clinical trials requires voluntary participation, informed consent, and protection of vulnerable populations [24].

9.2 Equity and Access

Biopharmaceuticals are often prohibitively expensive, raising issues of distributive justice. High prices limit access in low- and middle-income countries [25]. Ethical frameworks emphasize global health equity

9.3 Animal Welfare in Research

Preclinical testing traditionally involves animal models, sparking ethical concerns. Alternatives like organ-on-chip technology and computational modeling are being developed to reduce animal use [26].

9.4 Genetic Manipulation and Gene Therapy

Gene-editing tools such as CRISPR raise ethical debates over germline modification, long-term safety, and potential misuse [27]. Somatic therapies are generally accepted, while germline editing remains controversial.

9.5 Data Integrity and Transparency

Ethical responsibility requires accurate reporting of clinical trial outcomes and open access to trial data to prevent publication bias [28].

10. Market trends and Challenges

Ongoing trends in the biopharmaceutical industry indicate significant expansion in the bioprocessing sector, with more marketed products, growth in biosimilars, and rising investments in developing regions such as China. Key trends include the rising demand for personalized medicines, adoption of novel expansion platforms such as plant-based systems and cell-free proteins synthesis. Global manufacturing capacity now exceeds 17 million liters across 1900+ facilities, supported by trends toward single-use technologies, flexible and modular plants, and second-source sites to strengthen supply chains. Advances in continuous processing, higher titers, improved expression systems, automation, and bioprocess modeling are driving efficiency, while evolving regulatory frameworks will further shape innovation and global adoption [29].

Artificial Intelligence (AI) is increasingly being integrated into biopharmaceutical program management to enhance decision-making and efficiency. AI-driven approaches, such as machine learning (ML), natural language processing (NLP), and predictive analytics, allow for real-time insights, scenario analysis, and dynamic portfolio adjustments. AI can evaluate vast datasets— including clinical trial results, patient outcomes, regulatory trends, and market dynamics— enabling more precise forecasting and risk assessment [30].

The biopharmaceutical industry faces mounting challenges of cost, complexity, and regulatory scrutiny as it transitions from the scientific frontier to mainstream healthcare. Downward cost pressures are intensifying as payors and governments struggle with high treatment prices, pushing the growth of biosimilars to expand patient

access and reduce costs. At the same time, supply chain and operational complexity is increasing with the rise of multiproduct facilities, continuous manufacturing, and stringent cold-chain requirements. The introduction of novel modalities such as drug conjugates, cell, and gene therapies further complicates manufacturing and quality assurance, as companies struggle to establish optimal production systems. Regulatory demands are also rising, with the US FDA and global agencies issuing unprecedented levels of warnings, highlighting the need for greater compliance, process robustness, and efficiency. Together, these challenges will pressure biopharma to innovate while ensuring affordability, reliability, and patient accessibility [31].

11. Future prospect

The developing "-omics "Field (Genomics, Transcriptomics, Proteomics, Metabolomics, Epigenomics, Microbiomics) has enabled the biotechnology industry to improvise the revolution of the biopharmaceuticals with respect to:

11.1 Precision medicine/personalized medicine

hat we call as the "new age medicine" has Superseded the traditional methods. With the constant evolution of ecology, system biology and microbiology the old generic approach of "one size fits all" is slowly losing its significance.Based on genetic makeup, lifestyle and environment tailored drugs have made a huge impact pharmacogenomics , targeted therapies can also be applied to a larger scale with the help of various AI tools that can analyse big data of a subpopulation [32]. **Gene editing and cell therapies**: The ability to change the DNA sequence precisely of a living organism dates back to 1970s and ever since then it has made a paradigm shift in the field. Site-specific double-strand breaks in DNA, CRISPR-Cas nucleases have revolutionized the field of genome editing through their exceptional programmability[33]. May 15,2025 world's first personalized CRISPR therapy given to a baby named KJ with a rare genetic disorder called CPS1 deficiency was successfully treated. This has become A historic breakthrough in therapeutic development making it credible. Further advances by the biotechnology industry foresees the improvement in the guide design, delivery methods and detection technologies and reduction of unintended mistakes [34].Beyond CRISPR-Cas, recent discovery of TIGR-Tas (Tandem Interspaced Guide RNA-Targeting Systems) has become another major milestone of industry in 2025. This RNA – guided DNA targeting system has a unique dual space guide RNA that helps in the recognition of the double stranded target DNA without the need of PAM-protospacer adjacent motif. These discoveries have become as stepping stone for a better future of the industry [35]. Cell therapies such as Stem Cell Therapy, CAR-T Cell Therapy, Dendritic Cell Therapy and iPSC Therapy (Induced Pluripotent Stem Cells) have played potential roles in the curative treatment of complex diseases, Regenerating damaged tissues, fighting cancer, treating genetic or immune disorders have been the forefront of this field. Cell therapy has grown rapidly throughout the years and is seen as one of the promising remedies [36]. In the recent years, a pivotal moment where a man with type 1 diabetes has become the first ever patient to produce his own insulin and this is the result of genetically engineered cell transplants, without needing drugs to prevent rejection. Hence these methods have demonstrated dependability in future clinical settings [37]

11.2 Use of AI and Big Data

Artificial intelligence has massively flourished and has taken involvement in all the fields. The combination of Biotechnology and artificial intelligence is not a novel concept. AI has always played prominent roles in for example drug discovery, drug safety, functional and structural genomics, pharmacology, pharmacogenetics and pharmacogenomics many others

Development of digital technology along side with biotechnology is seen as a significant advantage. But it can be quite challenging for researchers to adapt and utilize it effectively to maximize the output. Managing personalized diagnostics, optimizing clinical trials with the help of AI has made it easier for the quicker and effective diagnosis of the diseases [38].

11.3 Advancing human genetics research

Genes have always been the bigger business, Human genome project (HGP) – an initiative led by the NHI (National Institutes of Health) US and international partners that aimed to map the entire human genome. With objectives of Determining the complete DNA sequence of the human genome and Develop tools for data analysis and sequencing technologies HGP laid the foundation for precision medicine, tailored therapeutics and much more [39].

12. Conclusion

The scope of biopharmaceuticals, their production technologies, analytical approaches, and regulatory frameworks represent a transformative field of medicine, combining biotechnology, computational sciences, and advanced manufacturing. Findings indicate that while biologics and biosimilars have significantly advanced modern therapeutics, challenges remain in cost, accessibility, and regulation. Emerging innovations such as mRNA therapeutics, monoclonal antibodies, and gene and cell therapies highlight the future potential of the field. Overall, biopharmaceuticals are poised to drive precision medicine and transform global healthcare**.**

Acknowledgment

We would like to express our sincere gratitude to **Rapture Biotech, Bengaluru**, and **JSS College of Arts, Commerce and Science, Mysuru,** for their encouragement, guidance, and support, and for providing us with the foundation to successfully complete this work.

Reference:

1. Aransiola, S. A., Victor-Ekwebelem, M. O., Ikhumetse, A. A., & Abioye, O. P. (2021). Challenges and future prospects of biotechnology. *Innovations in biotechnology for a sustainable future*, 429-438.

2. Zhang, K., & Liu, W. (2020). The current status, trend, and development strategies of Chinese biopharmaceutical industry with a challenging perspective. Sage Open, 10(1), 2158244020901529.

3. Kesik-Brodacka, M. (2018). Progress in biopharmaceutical development. Biotechnology and applied biochemistry, 65(3), 306-322.

4. Liao, C., Xiao, S., & Wang, X. (2023). Bench-to-bedside: Translational development landscape of biotechnology in healthcare. Health sciences review, 7, 100097.

5. Dasani, S., Palanki, R., Menon, P., & Bose, S. K. (2023). Biopharmaceuticals. In Translational Surgery (pp. 535-538). Academic Press.

6. Cosenza, M. E. (2025). Biologics. In An Overview of FDA Regulated Products (pp. 111-132). Academic Press.

7. Bhojaraj, S., Kumar, T. D. A., Ghosh, A. R., Sushmitha, B. S., Ramamurthy, S., Velusamy, T., ... & Qoronfleh, M. W. (2021). Biosimilars: an update. International Journal of Nutrition, Pharmacology, Neurological Diseases, 11(1), 7-16.

8. Szkodny, A. C., & Lee, K. H. (2022). Biopharmaceutical manufacturing: Historical perspectives and future directions. Annual Review of Chemical and Biomolecular Engineering, 13(1), 141-165.

9. Butler, M., & Meneses-Acosta, A. (2012). Recent advances in technology supporting biopharmaceutical production from mammalian cells. Applied microbiology and biotechnology, 96(4), 885-894.

10. Kulagina, N., Besseau, S., Godon, C., Goldman, G. H., Papon, N., & Courdavault, V. (2021). Yeasts as biopharmaceutical production platforms. Frontiers in Fungal Biology, 2, 733492.

11. Shanmugaraj, B., I. Bulaon, C. J., & Phoolcharoen, W. (2020). Plant molecular farming: a viable platform for recombinant biopharmaceutical production. Plants, 9(7), 842.

12. Zawada, J. F., Burgenson, D., Yin, G., Hallam, T. J., Swartz, J. R., & Kiss, R. D. (2022). Cell-free technologies for biopharmaceutical research and production. Current Opinion in Biotechnology, 76, 102719.

13. Veseli, A., Žakelj, S., & Kristl, A. (2019). A review of methods for solubility determination in biopharmaceutical drug characterization. *Drug development and industrial pharmacy*, *45*(11), 1717-1724.

14. Alhazmi, H. A., & Albratty, M. (2023). Analytical techniques for the characterization and quantification of monoclonal antibodies. *Pharmaceuticals*, *16*(2), 291.

15. Singh, D., & Tiwari, P. (Eds.). (2024). *9789815223026*. Bentham Science Publishers.

16. Anushiya M, Selvi G (2023). Recent Advances in Biopharmaceuticals: Expanding the Therapeutic Arsenal for Disease Treatment. International Journal of Pharmacometrics and Integrated Biosciences 8(2):18-22.

17. Kesik-Brodacka, M. (2018). Progress in biopharmaceutical development. *Biotechnology and applied biochemistry*, *65*(3), 306-322.

18. International Council for Harmonisation (ICH). (2016). ICH Harmonised Guidelines. Retrieved from https://www.ich.org

19. Food and Drug Administration (FDA). (2020). Biologics License Applications (BLA) Process. Retrieved from https://www.fda.gov

20. European Medicines Agency (EMA). (2021). Guidelines on Biological Medicines and Biosimilars. Retrieved from https://www.ema.europa.eu

21. Central Drugs Standard Control Organization (CDSCO). (2016). Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India. Government of India.

22. World Health Organization (WHO). (2017). Good Manufacturing Practices for Pharmaceutical Products.

23. World Health Organization (WHO). (2019). Guidelines on Evaluation of Biosimilars.

24. World Medical Association. (2013). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.

25. Kaplan, W., Wirtz, V., Mantel-Teeuwisse, A., Stolk, P., Duthey, B., & Laing, R. (2016). Priority Medicines for Europe and the World 2013 Update. World Health Organization.

26. Hartung, T. (2013). Look back in anger—what clinical studies tell us about preclinical work. ALTEX, 30(3), 275–291. https://doi.org/10.14573/altex.2013.3.275

27. Nuffield Council on Bioethics. (2018). Genome Editing and Human Reproduction: Social and Ethical Issues.

28. Chan, A. W., Song, F., Vickers, A., Jefferson, T., Dickersin, K., Gotzsche, P. C., ... & Krleža-Jerić, K. (2014). Increasing value and reducing waste: Addressing inaccessible research. The Lancet, 383(9913), 257–266. https://doi.org/10.1016/S0140-6736(13)62296-5

29. Lin, D. (2021). Trends Affecting Biopharmaceutical Manufacturing.

30. GEORGE, S., KATE, J., & FRANK, E. (2025). THE FUTURE OF AI-DRIVEN PORTFOLIO OPTIMIZATION IN BIOPHARMACEUTICAL PROGRAM MANAGEMENT.

31. Otto, R., Santagostino, A., & Schrader, U. (2014). Rapid growth in biopharma: Challenges and opportunities. McKinsey & Company, 1.

32. Naithani, N., Sinha, S., Misra, P., Vasudevan, B., & Sahu, R. (2021). Precision medicine: Concept and tools. medical journal armed forces india, 77(3), 249-257

33. Pacesa, M., Pelea, O., & Jinek, M. (2024). Past, present, and future of CRISPR genome editing technologies. Cell, 187(5), 1076-1100.

34. Ledford, H. World's first personalized CRISPR therapy given to baby with genetic disease. Nature

35. Ruden, D. M. (2025). TIGR-Tas and the Expanding Universe of RNA-Guided Genome Editing Systems: A New Era Beyond CRISPR-Cas. Genes, 16(8), 896.

36. Wang, B., Bowles-Welch, A. C., Yeago, C., & Roy, K. (2022). Process analytical technologies in cell therapy manufacturing: State-of-the-art and future directions. Journal of Advanced Manufacturing and Processing, 4(1), e10106.

37. Smith, L. (2025, August 13). *Diabetic man produces his own insulin after gene-edited cell transplant*. *Live Science*.

38. Holzinger, A., Keiblinger, K., Holub, P., Zatloukal, K., & Müller, H. (2023). AI for life: Trends in artificial intelligence for biotechnology. New biotechnology, 74, 16-24.

39. Gibbs, R. A. (2020). The human genome project changed everything. *Nature Reviews Genetics*, *21*(10), 575-576.

rebioin journal
OF BIOSCIENCES

"ADVANCES AND FUTURE PROSPECTS IN BIOTECHNOLOGY AND BIOPHARMACEUTICALS: TRANSLATING INNOVATIVE RESEARCH FROM BENCH TO BEDSIDE FOR NEXT-GENERATION THERAPIES."

Plot no 977, GMS Road, near Balliwala Flyover, opposite Cubic Plaza,
Dehradun, Uttarakhand 248001

admin@reboin.com

www.rebioin.com